PPARA and Glucose intolerance: PPAR modulators including agonists and antagonists could represent a novel strategy for preventing and treating multiple types of cancer, regarding that dyslipidemias, obesity, glucose intolerance, and low-grade inflammation are strongly related to an increased risk of cancer, which PPAR modulators are able to directly or indirectly regulate.